KRYSTAL BIOTECH INC (KRYS) Stock Fundamental Analysis
USA - NASDAQ:KRYS - US5011471027 - Common Stock
187.44 USD
+0.99 (+0.53%)
We assign a fundamental rating of 6 out of 10 to KRYS. KRYS was compared to 534 industry peers in the Biotechnology industry. While KRYS has a great health rating, its profitability is only average at the moment. A decent growth rate in combination with a cheap valuation! Better keep an eye on KRYS. This makes KRYS very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year KRYS was profitable.
KRYS had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: KRYS reported negative net income in multiple years.
KRYS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
KRYS's Return On Assets of 12.89% is amongst the best of the industry. KRYS outperforms 94.94% of its industry peers.
KRYS has a better Return On Equity (14.10%) than 94.19% of its industry peers.
With an excellent Return On Invested Capital value of 12.87%, KRYS belongs to the best of the industry, outperforming 95.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.89% | ||
| ROE | 14.1% | ||
| ROIC | 12.87% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KRYS's Profit Margin of 40.85% is amongst the best of the industry. KRYS outperforms 98.13% of its industry peers.
KRYS has a Operating Margin of 42.26%. This is amongst the best in the industry. KRYS outperforms 98.88% of its industry peers.
The Gross Margin of KRYS (93.37%) is better than 92.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.26% | ||
| PM (TTM) | 40.85% | ||
| GM | 93.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so KRYS is still creating some value.
KRYS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for KRYS has been increased compared to 5 years ago.
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
KRYS has an Altman-Z score of 34.54. This indicates that KRYS is financially healthy and has little risk of bankruptcy at the moment.
KRYS has a better Altman-Z score (34.54) than 95.13% of its industry peers.
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 34.54 |
ROIC/WACC1.38
WACC9.31%
2.3 Liquidity
KRYS has a Current Ratio of 9.68. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
KRYS has a Current ratio of 9.68. This is amongst the best in the industry. KRYS outperforms 80.52% of its industry peers.
KRYS has a Quick Ratio of 9.33. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
KRYS has a better Quick ratio (9.33) than 79.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.68 | ||
| Quick Ratio | 9.33 |
3. Growth
3.1 Past
KRYS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 2794.12%, which is quite impressive.
The Revenue has grown by 116.08% in the past year. This is a very strong growth!
EPS 1Y (TTM)2794.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%143.4%
Revenue 1Y (TTM)116.08%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%36.65%
3.2 Future
Based on estimates for the next years, KRYS will show a very strong growth in Earnings Per Share. The EPS will grow by 60.52% on average per year.
The Revenue is expected to grow by 32.95% on average over the next years. This is a very strong growth
EPS Next Y70.26%
EPS Next 2Y61.86%
EPS Next 3Y54.61%
EPS Next 5Y60.52%
Revenue Next Year32.01%
Revenue Next 2Y39.7%
Revenue Next 3Y41.08%
Revenue Next 5Y32.95%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 38.10 indicates a quite expensive valuation of KRYS.
KRYS's Price/Earnings ratio is rather cheap when compared to the industry. KRYS is cheaper than 92.70% of the companies in the same industry.
KRYS is valuated rather expensively when we compare the Price/Earnings ratio to 26.83, which is the current average of the S&P500 Index.
KRYS is valuated rather expensively with a Price/Forward Earnings ratio of 23.93.
KRYS's Price/Forward Earnings ratio is rather cheap when compared to the industry. KRYS is cheaper than 91.76% of the companies in the same industry.
KRYS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.1 | ||
| Fwd PE | 23.93 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, KRYS is valued cheaper than 92.88% of the companies in the same industry.
94.01% of the companies in the same industry are more expensive than KRYS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.25 | ||
| EV/EBITDA | 27.95 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of KRYS may justify a higher PE ratio.
A more expensive valuation may be justified as KRYS's earnings are expected to grow with 54.61% in the coming years.
PEG (NY)0.54
PEG (5Y)N/A
EPS Next 2Y61.86%
EPS Next 3Y54.61%
5. Dividend
5.1 Amount
KRYS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:KRYS (10/24/2025, 10:55:37 AM)
187.44
+0.99 (+0.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.05%
Inst Owner Change0.12%
Ins Owners11.86%
Ins Owner Change-1.19%
Market Cap5.42B
Revenue(TTM)359.20M
Net Income(TTM)146.72M
Analysts84.44
Price Target209.94 (12%)
Short Float %14.53%
Short Ratio9.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.87%
Min EPS beat(2)-13.89%
Max EPS beat(2)12.14%
EPS beat(4)2
Avg EPS beat(4)6.3%
Min EPS beat(4)-13.89%
Max EPS beat(4)27.68%
EPS beat(8)3
Avg EPS beat(8)-4.07%
EPS beat(12)5
Avg EPS beat(12)-8.82%
EPS beat(16)7
Avg EPS beat(16)-7.79%
Revenue beat(2)1
Avg Revenue beat(2)-3.87%
Min Revenue beat(2)-10.17%
Max Revenue beat(2)2.42%
Revenue beat(4)1
Avg Revenue beat(4)-2.48%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)2.42%
Revenue beat(8)4
Avg Revenue beat(8)8.28%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.05%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)-17.84%
EPS NY rev (1m)0.57%
EPS NY rev (3m)-11.52%
Revenue NQ rev (1m)-0.16%
Revenue NQ rev (3m)-9.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.1 | ||
| Fwd PE | 23.93 | ||
| P/S | 15.1 | ||
| P/FCF | 29.25 | ||
| P/OCF | 27.76 | ||
| P/B | 5.21 | ||
| P/tB | 5.21 | ||
| EV/EBITDA | 27.95 |
EPS(TTM)4.92
EY2.62%
EPS(NY)7.83
Fwd EY4.18%
FCF(TTM)6.41
FCFY3.42%
OCF(TTM)6.75
OCFY3.6%
SpS12.41
BVpS35.96
TBVpS35.96
PEG (NY)0.54
PEG (5Y)N/A
Graham Number63.09
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.89% | ||
| ROE | 14.1% | ||
| ROCE | 14.44% | ||
| ROIC | 12.87% | ||
| ROICexc | 36.62% | ||
| ROICexgc | 36.62% | ||
| OM | 42.26% | ||
| PM (TTM) | 40.85% | ||
| GM | 93.37% | ||
| FCFM | 51.63% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 195.35% | ||
| Cap/Sales | 2.77% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 124.54% | ||
| Profit Quality | 126.39% | ||
| Current Ratio | 9.68 | ||
| Quick Ratio | 9.33 | ||
| Altman-Z | 34.54 |
F-Score8
WACC9.31%
ROIC/WACC1.38
Cap/Depr(3y)537.2%
Cap/Depr(5y)976.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2794.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%143.4%
EPS Next Y70.26%
EPS Next 2Y61.86%
EPS Next 3Y54.61%
EPS Next 5Y60.52%
Revenue 1Y (TTM)116.08%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%36.65%
Revenue Next Year32.01%
Revenue Next 2Y39.7%
Revenue Next 3Y41.08%
Revenue Next 5Y32.95%
EBIT growth 1Y3666.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year149.9%
EBIT Next 3Y73.68%
EBIT Next 5YN/A
FCF growth 1Y242.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y290.87%
OCF growth 3YN/A
OCF growth 5YN/A
KRYSTAL BIOTECH INC / KRYS FAQ
Can you provide the ChartMill fundamental rating for KRYSTAL BIOTECH INC?
ChartMill assigns a fundamental rating of 6 / 10 to KRYS.
What is the valuation status of KRYSTAL BIOTECH INC (KRYS) stock?
ChartMill assigns a valuation rating of 7 / 10 to KRYSTAL BIOTECH INC (KRYS). This can be considered as Undervalued.
What is the profitability of KRYS stock?
KRYSTAL BIOTECH INC (KRYS) has a profitability rating of 6 / 10.
What is the financial health of KRYSTAL BIOTECH INC (KRYS) stock?
The financial health rating of KRYSTAL BIOTECH INC (KRYS) is 8 / 10.